NA-921 (Bionetide)™is a small molecule drug that is in Phase 3 clinical trials for the treatment of Rett Syndrome.
How does NA-921 (Bionetide™) work?
NA-921 (Bionetide) can easily cross the blood brain barrier, so only a small dose of the drug is required to be effective. The drug shows the following properties:
* NA-921 exhibits neuroprotection
* NA-921 exhibits neurogenesis, i.e. ability to generate new neurons
* It has great bioavailability in the body
* It is very safe, with no toxicity observed
* It is available in oral formulation
PHASE 2/3 CLINICAL TRIALS of NA-921
Biomed has completed Phase 2/3 clinical trials of NA-921 for the treatment of Rett Syndrome:
To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett Syndrome
ClinicalTrials.gov ID NCT06849973
A Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of NA-921 (Bionetide) for the Treatment of Girls and Women with Rett Syndrome
Primary Objective • To investigate the efficacy and safety of treatment with oral NA-921 (Bionetide) versus placebo in girls and women with Rett syndrome
Key Secondary Objective • To investigate the efficacy of treatment with oral NA-921 (Bionetide) versus placebo on ability to communicate in girls and women with Rett syndrome
The Results of the Phase 2/3 has been announced:
PHASE 3 CLINICAL TRIALS OF NA-921
The Phase 3 clinical protocol "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Bionetide for the Treatment of Girls and Women With Rett Syndrome" has been posted on https://clinicaltrials.gov of the National Institute of Health- United States of America.
ClinicalTrials.gov ID NCT06840496
HOW TO PARTICIPATE IN A PHASE 3 CLINICAL TRIAL OF NA-921
If you wish to participate as a patient or a care-giver of the patient, please complete the online form.
For further information about our products, please contact us. Contact us